Tag Archives: Atypical Antipsychotics

NICE Update on Antipsychotics for People With Dementia (NICE)

Posted on March 28, 2019 by Dementia and Elderly Care News

Summary The National Institute for Health and Care Excellence (NICE) has again updated their summary of evidence on the use (or withdrawal) of antipsychotics for people living with dementia. This document is not a formal NICE guideline. Full Text Link … Continue reading →

Posted in Acute Hospitals, Antipsychotics, Commissioning, Community Care, Falls Prevention, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, SCIE, Systematic Reviews, UK, Universal Interest | Tagged Alive Approach to Provision of Meaningful Activities for Older People Living in Care, Alternatives to Antipsychotic Drugs, Alternatives to Antipsychotic Medication, Antipsychotic Drugs, Antipsychotic Prescribing in Primary Care, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics in People With Dementia, Antipsychotics in People With Dementia: Key Therapeutic Topic [KTT7], Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Atypical Antipsychotics, Avoidable Harm, Avoidable Mortality, Behavioural and Psychological Symptoms of Dementia (BPSD), Inappropriate Use of Antipsychotics in Dementia, Later Life, Long Term Plan (LTP), Medicines Optimisation, Mellifont Abbey Residential Care Home, Mental Health and Illness, Milton Keynes Primary Care Trust, National Institute for Health and Care Excellence (NICE), National Institute for Health and Care Excellence (NICE)’s Quality Standard on Dementia: 2019 Draft For Consultation, Neurological Disorders, NHS England Medicines Optimisation Intelligence Group, NICE Key Therapeutic Topic [KTT7], NICE Key Therapeutic Topics, Potential Harms of Antipsychotic Use, Prescribing of Antipsychotic Drugs For People With Dementia, Prevalence of Potentially Inappropriate Prescribing of Antipsychotic Drugs, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Social Care Institute for Excellence (SCIE) | Leave a comment

Pharmacological Treatment of Agitation in Persons With Dementia (British Journal of Clinical Pharmacology)

Posted on April 17, 2018 by Dementia and Elderly Care News

Summary A systematic review and meta‐analysis of pharmaceutical treatments for alleviating agitation in dementia has been performed. Regarding the efficacy and treatment acceptability of these medications, it is reported that: “Risperidone, SSRIs as a class and Dextromethorphan / Quinidine demonstrated … Continue reading →

Posted in Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Pharmacological Treatments, Quick Insights, Systematic Reviews | Tagged Agitation, Agitation and Aggression, Antidepressants, Antidepressants for Agitation and Psychosis in Dementia, Antipsychotics in Elderly People with Dementia, Asian Centre for Evidence Synthesis in Population Implementation and Clinical Outcomes (PICO): Monash University Malaysia, Atypical Antipsychotics, Australia, Behavioural and Psychological Symptoms of Dementia (BPSD), Behavioural Problems, Behavioural Problems in People With Dementia, BPSD: Behavioral and Psychological Symptoms of Dementia, British Journal of Clinical Pharmacology, Center of Pharmaceutical Outcomes Research (CPOR): Naresuan University, Centre for Medicine Use and Safety: Monash University, Chulalongkorn University (Bangkok), Dementia-Related Agitation, Department of Clinical Pharmacy: Mahasarakham University, Department of Pharmacy Practice: Naresuan University, Department of Psychiatry: King Chulalongkorn Memorial Hospital, Dextromethorphan / Quinidine (DM/Q: Nuedexta™), Faculty of Medicine: Chulalongkorn University, Faculty of Pharmaceutical Sciences: Naresuan University, Faculty of Pharmacy and Pharmaceutical Sciences: Monash University, Haloperidol, Health and Well-being Cluster - Global Asia in the 21st Century (GA21) Platform: Monash University Malaysia, Interventions for BPSD, King Chulalongkorn Memorial Hospital, Kolling Institute of Medical Research: Royal North Shore Hospital, Mahasarakham University (Thailand), Malaysia, Managing Agitation, Medication-Related Risks, Medications: Best Usage, Medicines Optimisation, Monash University, Monash University Malaysia, Mood Disturbances, Naresuan University (Thailand), Neuroleptics, Neuropsychiatric Symptoms (NPS), Neuropsychiatric Symptoms in People With Dementia, Oxcarbazepine, Patient Safety, Potentially Inappropriate Medications (PIM), Potentially Inappropriate Prescribing (PIP), Potentially Inappropriate Prescribing in Advanced Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Psychotropic Drugs, Psychotropic Medication, Psychotropic Prescribing, Reducing Agitation and Distress, Risperidone, Royal North Shore Hospital (Australia), School of Pharmacy: Monash University Malaysia, Selective Serotonin Reuptake Inhibitors (SSRIs), SSRIs: Selective Serotonin Reuptake Inhibitors, Systematic Reviews and Meta-Analyses, Thailand, University of Sydney | Leave a comment

Update to Evidence on Antipsychotics in People With Dementia (NICE)

Posted on March 1, 2018 by Dementia and Elderly Care News

Summary The National Institute for Health and Care Excellence (NICE) has published an updated summary of the evidence on safer use (or withdrawal) of antipsychotics for people living with dementia. This document is not a formal NICE guideline. Full Text … Continue reading →

Posted in Acute Hospitals, Antipsychotics, Commissioning, Community Care, Falls Prevention, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, SCIE, Systematic Reviews, UK, Universal Interest | Tagged Alternatives to Antipsychotic Drugs, Alternatives to Antipsychotic Medication, Antipsychotic Drugs, Antipsychotic Prescribing in Primary Care, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics in People With Dementia, Antipsychotics in People With Dementia: Key Therapeutic Topic [KTT7], Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Atypical Antipsychotics, Avoidable Harm, Avoidable Mortality, Behavioural and Psychological Symptoms of Dementia (BPSD), Inappropriate Use of Antipsychotics in Dementia, Later Life, Medicines Optimisation, Mental Health and Illness, National Institute for Health and Care Excellence (NICE), Neurological Disorders, NHS England Medicines Optimisation Intelligence Group, NICE Key Therapeutic Topic [KTT7], NICE Key Therapeutic Topics, Potential Harms of Antipsychotic Use, Prescribing of Antipsychotic Drugs For People With Dementia, Prevalence of Potentially Inappropriate Prescribing of Antipsychotic Drugs, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Social Care Institute for Excellence (SCIE) | Leave a comment

Review of Non-Pharmacological Interventions for Dementia-Related Agitation: Including a Brief Analysis of the Risks and Benefits of Drug Treatments (Translational Psychiatry)

Posted on October 31, 2017 by Dementia and Elderly Care News

Summary A recently published literature review evaluates the best available evidence on the effectiveness of various non-pharmacological interventions for reducing dementia-related agitation. The author also briefly addresses current viewpoints on balancing the risks and benefits of pharmacotherapy in the management … Continue reading →

Posted in Acute Hospitals, Antipsychotics, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Local Interest, Management of Condition, Mental Health, Models of Dementia Care, New Cross Hospital, Non-Pharmacological Treatments, Person-Centred Care, Personalisation, Pharmacological Treatments, Quick Insights, Royal Wolverhampton NHS Trust, Royal Wolverhampton NHS Trust Authorial Affiliation, Systematic Reviews, UK, Universal Interest, Wolverhampton | Tagged ACADIA Pharmaceuticals, Agitation, Agitation and Aggression, Alternatives to Antipsychotic Drugs, Animal Assisted Therapy, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Aromatherapy, Arts and Music in Dementia, Atypical Antipsychotics, Avanir Pharmaceuticals Inc (California), Behavioural Alternatives to Antipsychotic Drugs, Behavioural and Psychological Symptoms of Dementia (BPSD), Behavioural Problems, Behavioural Problems in People With Dementia, Behavioural Variant Frontotemporal Dementia (bvFTD), BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Carbamazepine, Citalopram, Citalopram for Agitation in Alzheimer's Disease: CitAD Trial, Cognitive Behavioral Therapy, Dementia-Related Agitation, Department of Medicine: Royal Wolverhampton NHS Trust, Describe Investigate Create and Evaluate (DICE) Approach, East Kent Hospitals University NHS Foundation Trust, Electroconvulsive Therapy for Agitation and Aggression in Dementia, Improving the Quality of Life for People With Dementia, Interventions for BPSD, Intra-Cellular Therapies, Medication-Related Risks, Medications: Best Usage, Medicines Optimisation, Memantine, Mirtazapine, Mood Disturbances, Multisensory Stimulation, Music Therapy, Music Therapy for BPSD, Music-Based Therapeutic Interventions, Nature Publishing Group, Neuroleptic Discontinuation, Neuroleptics, Neuropsychiatric Symptoms (NPS), Neuropsychiatric Symptoms in People With Dementia, Non-Pharmacological Management of Symptoms, Non-Pharmacological Treatments, Otsuka Pharmaceuticals Limited, Pharmacological Treatments, Potential Harms of Antipsychotic Use, Potentially Inappropriate Medications (PIM), Potentially Inappropriate Prescribing (PIP), Potentially Inappropriate Prescribing in Advanced Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Quetiapine, Reducing Inappropriate Use of Antipsychotics in Dementia, Risperidone, Simulated Presence Therapy (SPT), Simulated Presence Therapy for BPSD, Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME), Translational Psychiatry, Withdrawal of Neuroleptic Medications | Leave a comment

Historic Reduction in the Use of Antipsychotics for BPSD in UK General Practice? (Drug Safety)

Posted on August 23, 2017 by Dementia and Elderly Care News

Summary Data from 111,346 patients with dementia but without a concomitant diagnosis of psychosis indicates that prescribing of certain categories of antipsychotic drugs did reduce from 8.9% in 2001 to 1.4% in 2014. At face value, this reduction in inappropriate … Continue reading →

Immovable Antipsychotic Prescribing Practices in Care Homes? (BMJ Open)

Posted on September 23, 2016 by Dementia and Elderly Care News

Summary Incredible as it may seem, and contrary to years of high-level campaigning plus the circulation of awareness raising reports and guidelines, antipsychotic prescribing in long-term residential care in England did not, in fact, decline measurably during the four years … Continue reading →

Posted in Antipsychotics, Commissioning, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK, Universal Interest | Tagged Alternatives to Antipsychotic Drugs, Alternatives to Antipsychotic Medication, Antipsychotic Drugs, Antipsychotic Prescribing in Care Homes, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Atypical Antipsychotics, Avoidable Harm, Avoidable Mortality, Behavioural and Psychological Symptoms of Dementia (BPSD), BMJ Open, BMJ Publishing Group Ltd, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, City University London, Coventry, Coventry University, Department Mathematics and Statistics: Lancaster University, Discontinuation of Antipsychotics, English National Dementia Strategy, Faculty of Health and Life Sciences: Coventry University, Inappropriate Use of Antipsychotics in Dementia, Institute for Employment Research: University of Warwick, Invatech Health Ltd, Lancaster, Lancaster University, Management of Medicines, National Dementia Strategy, Neuroleptic Discontinuation, Neuroleptics, Norwich Medical School: University of East Anglia, Potential Harms of Antipsychotic Use, Prescribing of Antipsychotic Drugs For People With Dementia, Psychological Symptoms of Dementia (BPSD), Qualitative Research, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, School of Health Sciences: City University London, University of East Anglia, University of Warwick, Withdrawal of Neuroleptic Medications | 1 Comment

Introducing the Journal of Geriatric Care and Research (JGCR)

Posted on July 3, 2016 by Dementia and Elderly Care News

Summary The Journal of Geriatric Care and Research (ISSN 2397-5628) is a recently launched, locally edited, multi-disciplinary peer-reviewed international journal, which covers topics of relevance to the care of the elderly. Concerning Guidelines on the Use of Antipsychotics for Agitation … Continue reading →

Posted in Acute Hospitals, Antipsychotics, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Guidelines, International, Local Interest, Management of Condition, Mental Health, Models of Dementia Care, Person-Centred Care, Pharmacological Treatments, Quick Insights, Wales, Wolverhampton | Tagged Academia.edu, Adverse Drug Reactions (ADRs), Adverse Drug Reactions in the Elderly, Adverse Effects, Aggression, Aggressive Behaviour, Agitation, Agitation and Aggression, Alternatives to Antipsychotics, Alzheimer’s Disease-Related Agitation, American Journal of Psychiatry, American Psychiatric Association (APA), American Psychiatric Association: Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia (2016), Antipsychotic Drugs, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Neuroleptic Sensitivity, APA Practice Guidelines, Aripiprazole, Atypical Antipsychotics, Avoidable Harm, Avoidable Hospital Mortality, Avoidable Mortality, Behavioural and Psychological Symptoms of Dementia (BPSD), Benefits and Risks of Antipsychotic Treatment, Betsi Cadwaladr University Health Board, Black Country, Black Country Partnership NHS Foundation Trust, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, British Indian Psychiatric Association (BIPA), Community and Mental Health Trusts, Dr Sarmishtha Bhattacharyya: Consultant in Old Age Psychiatry at Wrexham Maelor Hospital, Faculty of Health and Social Care: University of Chester, Geriatric Care and Research Organisation (GeriCaRe), Haloperidol, Improving Prescribing Practice, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, Journal of Geriatric Care and Research (JGCR), Learning Disabilities, Medication Reviews, Mental Health Trusts, North Wales, Olanzapine, Over-Medication, Over-Medication for People With Learning Disabilities, Over-Prescribing, Overprescribing, People With Learning Disabilities, Personalised Care Versus Guideline-Based Care, Personalised Medicine Versus Guideline-Based Medicine, Potential Harms of Antipsychotic Use, Potentially Inappropriate Prescribing, Prescribing Anti-Psychotic Drugs to People with Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Prescribing of Antipsychotic Drugs For People With Learning Disabilities, Psychosis in Patients With Dementia, Quetiapine, Reducing Agitation and Distress, Reducing Antipsychotic Prescriptions in Dementia, Reducing Avoidable Premature Mortality, Reducing Inappropriate Use of Antipsychotics, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Violence and Aggression, Risperidone, Safe and Compassionate Care, United States, University of Chester, USA, Violence and Aggression, West Midlands, Wrexham, Wrexham Maelor Hospital, Ziprasidone | Leave a comment

Reducing Antipsychotic Prescribing for BPSD (BMJ / JAMA / JAMA Psychiatry / BJCP)

Posted on November 6, 2014 by Dementia and Elderly Care News

Summary This BMJ “Change page” article discusses the potential harms associated with use of antipsychotics in people with dementia, and covers guidelines recommending restrictions in their use. Risperidone is the antipsychotic recommended for use in the treatment of aggression associated … Continue reading →

Posted in Acute Hospitals, Antipsychotics, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Standards, Statistics, UK | Tagged Adverse Drug Reactions (ADRs), Adverse Drug Reactions (ADRs): Type A (Potentially Avoidable and Associated With Commonly Prescribed Medications), Adverse Drug Reactions in the Elderly, Adverse Effects, Aggression, Aggressive Behaviour, Alternatives to Antipsychotics, Antidepressants, Antihypertensives, Antipsychotic Drugs, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Absolute Mortality Risk Increase, Antipsychotics: Neuroleptic Sensitivity, Antipsychotics: Number Needed to Harm (NNH), Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), Benzodiazepines, BMJ, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Brief Psychosocial Treatment, British Journal of Clinical Pharmacology, British Medical Journal (BMJ), Campbell Institute (CAMH): University of Toronto, Cardiff University, Center for Clinical Management Research: Veterans Affairs Ann Arbor Healthcare System (Michigan), Center for Statistical Consultation and Research: University of Michigan, CitAD Research Group, Citalopram for Agitation in Alzheimer's Disease: CitAD Trial, Clinical Biotechnology Research Institute: Roper St Francis Healthcare (Charleston: South Carolina), College of Physicians and Surgeons of Columbia University, DART-AD: Dementia Antipsychotic Withdrawal Trial (DART-AD), Dementia Antipsychotic Withdrawal Trial (DART-AD), Department of Psychiatry: University of Michigan, Department of Psychiatry: University of Southern California, Discontinuation of Antipsychotics, Effect of Citalopram on Agitation in Alzheimer Disease (CitAD Randomized Clinical Trial), Falls Prevention, Hotchkiss Brain Institute: University of Calgary, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, International Conference on Harmonization, JAMA, JAMA Psychiatry, Johns Hopkins Bayview and Johns Hopkins School of Medicine, Johns Hopkins Bloomberg School of Public Health: Baltimore, Kings College London, Medication Reviews, National Institute for Health Research (NIHR): Mental Health Biomedical Research Centre and Dementia Unit, NEST Approach, Neuroleptic Discontinuation, Neuroleptics, New York State Psychiatric Institute, Patients’ Needs and the Environment Stimulation and Techniques (NEST), Perelman School of Medicine: University of Pennsylvania, Personalised Social Interaction, Pharmacokinetics, Polypharmacy, Potential Harms of Antipsychotic Use, Prescribing Anti-Psychotic Drugs to People with Dementia, Reducing Agitation and Distress, Reducing Antipsychotic Medication in Care Homes, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Violence and Aggression, Risperidone, Seattle Protocols, Simulated Presence Therapy, South London and Maudsley NHS Foundation Trust, Stanford University School of Medicine, United States, University Hospital Llandough (Cardiff), University of Calgary, University of Manchester, University of Michigan, University of Pennsylvania, University of Rochester School of Medicine and Dentistry, University of Southern California, University of Southern California Keck School of Medicine, University of Toronto, Violence and Aggression, Wolfson Centre for Age-Related Diseases: King’s College London | Leave a comment

Reducing Antipsychotic Prescriptions for Dementia in Primary Care (HSJ / NHS London)

Posted on September 26, 2014 by Dementia and Elderly Care News

Summary The Dementia and Prescribing Antipsychotic Project, run by London-based CCGs, helped to reduce prescribing levels by between 48% and 77%. The project aimed to raise awareness of the risks of antipsychotic prescribing for behavioural and psychological symptoms in dementia. … Continue reading →

Posted in Antipsychotics, Commissioning, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, NHS, Non-Pharmacological Treatments, Patient Care Pathway, Patient Information, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Standards, UK, Universal Interest | Tagged Antipsychotic Drugs, Antipsychotic Prescribing in Care Homes, Antipsychotic Prescribing in Nursing Homes, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Neuroleptic Sensitivity, Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), Bexley, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Bromley, Care Homes, CCGs, Clinical Commissioning Groups (CCGs), Community Care, Community Care Services, Community Pharmacists, Croydon, Dementia and Prescribing Antipsychotic Project, Differemtial Antipsychotic-Related Mortality Risks, Differential Risk of Death (Antipsychotic Drugs), Distressed Behaviour, East and South East Specialist Pharmacy Services, General Practice, GP Clusters, GPs, Guideline on Supporting People with Dementia and Their Carers in Health and Social Care, Guys and St Thomas Foundation Trust, Health Service Journal (HSJ), Home and Community Care Services, HSJ, Inappropriate Use of Antipsychotics in Dementia, Integrated Care Services, Integrated Commissioning, Integration of Pharmacy Into Community Care, Local Commissioning, London Antipsychotics Audit and Reduction Exercise in Primary Care, London GP Practice Audit of Antipsychotic Prescribing to People With Dementia, London Primary Care, Managing Medicines in Care Homes, Managing Psychological and Behavioural Distress in People with Dementia, Medicines Management, Medicines Management Audits, Mental Health Pharmacists, NHS London, NHSL Antipsychotic GP Audit, NICE Clinical Guideline 42. Dementia: Supporting People With Dementia And Their Carers In Health And Social Care, NICE–SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care, Pharmacists, Prescribing Anti-Psychotic Drugs to People with Dementia, Primary Care, Psychological Symptoms of Dementia (BPSD), Quality and Outcomes Framework (QOF), Reducing Agitation and Distress, Reducing Antipsychotic Medication in Care Homes, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Richmond, Supporting People with Dementia and Their Carers in Health and Social Care, Wandsworth | Leave a comment

Pharmacological Treatments for Neuropsychiatric Symptoms in Alzheimer’s Disease (Journal of Neurology Neurosurgery and Psychiatry)

Posted on June 25, 2014 by Dementia and Elderly Care News

Summary This systematic review investigates the efficacy and safety of various pharmacological treatments for neuropsychiatric symptoms in Alzheimer’s Disease patients. It concludes that cholinesterase inhibitors (ChEIs) and atypical antipsychotics could improve neuropsychiatric symptoms in these patients, but with poor patient … Continue reading →

Posted in Antipsychotics, Depression, For Doctors (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Systematic Reviews | Tagged Adverse Drug Reactions, Adverse Effects, Adverse Events, Antidepressants, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Neuroleptic Sensitivity, Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), Benzodiazepines, Benzodiazepines for BPSD, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Cerebrovascular Adverse Events, ChEIs: Cholinesterase Inhibitors, China, Cholinesterase Inhibitors, Journal of Neurology Neurosurgery and Psychiatry, Memantine, Mood Stabilisers, Nanjing Medical University, Neuropsychiatric Inventory (NPI), Neuropsychiatric Symptoms in Alzheimer’s Disease, Patient Safety, Pharmacological Treatments for Neuropsychiatric Symptoms in Alzheimer’s Disease, Qingdao Municipal Hospital, Qingdao University, Serious Adverse Events, Shandong Province, Systematic Reviews and Meta-Analyses | Leave a comment

Tag Archives: Atypical Antipsychotics

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites